We thank John P Neoptolemos and colleagues for their letter. They state that the ESPAC-1 trial set the standard of care for adjuvant therapy in resectable pancreatic cancer.1 However, ESPAC-1 set the standard of care for resected pancreatic cancer, including only those patients who had no occult metastases at surgery, underwent a resection, recovered from surgery, had no early recurrence,…
[Correspondence] The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer – Authors' reply
The Lancet Oncology | | Quisette P Janssen, Jacob L van Dam, Marc G Besselink, Johanna W Wilmink, Marjolein Y V Homs, Geertjan van Tienhoven, Casper H J van Eijck, Bas Groot Koerkamp
Topics: pancreatic-cancer